# Maria Elvira Salazar Bought Up to $100,000 in BIIB Stock
Rep. Maria Elvira Salazar (R-FL) purchased between $50,001 and $100,000 worth of Biogen Inc. (NASDAQ: BIIB) stock on May 11, 2026, according to congressional disclosure filings. The Florida Republican disclosed the biotechnology investment on June 8, 2026, nearly a month after executing the trade. This represents a significant investment in one of the largest biotechnology companies focused on neurological disorders.
What Does Biogen Do?
Biogen is a Massachusetts-based biotechnology company specializing in treatments for neurological and neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. The company's flagship products include Tecfidera and Tysabri for multiple sclerosis, and the controversial Alzheimer's drug Aduhelm. BIIB stock has been volatile in recent years due to mixed clinical trial results and regulatory challenges, making Salazar's purchase timing particularly noteworthy for investors tracking congressional trades.
Political Context and Timing
As a member of the House Foreign Affairs Committee and Small Business Committee, Salazar doesn't sit on panels directly overseeing healthcare policy or pharmaceutical regulation. However, her timing coincides with broader congressional discussions about Medicare drug pricing and FDA approval processes. The purchase came during a period when biotechnology stocks were experiencing renewed investor interest following several positive clinical trial announcements across the sector. There's no immediate indication that Salazar had access to non-public information that would directly impact Biogen's stock price.
Disclosure Timeline Analysis
Salazar disclosed her BIIB purchase 28 days after the trade date, which falls within the legally required 45-day window under the STOCK Act. While compliant, this represents a longer disclosure period compared to some colleagues who report trades within 1-2 weeks. The 28-day delay is relatively typical among congressional members, though transparency advocates often push for faster disclosure to maintain public trust.
Investment Implications
While congressional stock trades often generate retail investor interest, following politician investments isn't a guaranteed strategy. Salazar's BIIB purchase reflects confidence in the biotechnology sector, but investors should conduct their own research rather than blindly following congressional trades. The substantial investment size suggests conviction in Biogen's prospects, though the stock's inherent volatility requires careful consideration of risk tolerance.